Physician profile
Christopher Perez
NPI 1932635851
$34,007.87
in general payments reported to CMS, 2019-2025
18 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $244 · 2022: $714 · 2023: $5,938 · 2024: $13K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $14K · Travel and Lodging: $9,350 · Food and Beverage: $9,167 · Education: $892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $13,641.00 |
| Travel and Lodging | $9,350.06 |
| Food and Beverage | $9,166.51 |
| Education | $891.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20,118.25 | 2021-2025 | Assurity, Gallant, Cardiomems |
| Boston Scientific Corporation | $6,745.98 | 2024-2025 | Farapulse, General - Therapies, Emblem Mri S-Icd |
| Medtronic, INC. | $4,238.53 | 2023-2025 | Micra, Advisa Dr Mri Surescan, Azure Xt Dr Mri Surescan |
| Biosense Webster, INC. | $992.67 | 2025 | Carto 3 |
| Abiomed | $553.45 | 2022-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $350.55 | 2022-2025 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $155.50 | 2022-2024 | Tezspire, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $151.02 | 2022-2023 | Eliquis, Camzyos |
| Lantheus Medical Imaging, INC. | $138.77 | 2022 | |
| Novo Nordisk INC | $131.24 | 2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $104.18 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $101.89 | 2022-2024 | Verquvo |
| Cmp Pharma, INC. | $101.64 | 2022 | |
| Imperative Care, INC | $42.08 | 2025 | Symphony Catheter |
| Aurinia Pharma U.S., INC. | $22.17 | 2023 | Lupkynis |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $22.02 | 2023 | Xarelto |
| Pfizer INC. | $21.00 | 2022 | |
| Chiesi USA, INC. | $16.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.